Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
590M
-
Number of holders
-
1258
-
Total 13F shares, excl. options
-
478M
-
Shares change
-
-601K
-
Total reported value, excl. options
-
$45.6B
-
Value change
-
+$212M
-
Put/Call ratio
-
0.86
-
Number of buys
-
555
-
Number of sells
-
-560
-
Price
-
$95.56
Significant Holders of Edwards Lifesciences Corp - Common Stock (EW) as of Q1 2024
1,415 filings reported holding EW - Edwards Lifesciences Corp - Common Stock as of Q1 2024.
Edwards Lifesciences Corp - Common Stock (EW) has 1,258 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 478M shares
of 590M outstanding shares and own 80.9% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (53M shares), BlackRock Inc. (52.4M shares), STATE STREET CORP (26.8M shares), Bank of New York Mellon Corp (19M shares), BROWN ADVISORY INC (16.6M shares), ALLIANCEBERNSTEIN L.P. (16.4M shares), WELLINGTON MANAGEMENT GROUP LLP (15.5M shares), GEODE CAPITAL MANAGEMENT, LLC (13.1M shares), JPMORGAN CHASE & CO (9.6M shares), and NORGES BANK (8.39M shares).
This table shows the top 1258 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.